专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170269078A1 METHOD OF DETECTING AUTO-ANTIBODIES FROM PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS, A PEPTIDE AND ASSAY KIT 审中-公开
公开(公告)号：US20170269078A1
公开(公告)日：2017-09-21
申请号：US15610398
申请日：2017-05-31
申请人： STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN
发明人： Waltherus Jacobus Wilhelmus VAN VENROOIJ , Jan Wouter DRIJFHOUT , Martinus Adrianus Maria VAN BOEKEL , Gerardus Jozef Maria PRUIJN
IPC分类号： G01N33/564 , C07K14/47 , C07K7/64 , C07K7/52 , C07K7/08
CPC分类号： G01N33/564 , C07K7/08 , C07K7/52 , C07K7/64 , C07K14/4713 , G01N2410/00 , G01N2800/102 , Y10S435/973 , Y10S435/975 , Y10S530/806
摘要： Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.

2. 发明授权

US09249233B2 IgE CH3 peptide vaccine 有权
标题翻译： IgE CH3肽疫苗
公开(公告)号：US09249233B2
公开(公告)日：2016-02-02
申请号：US14225258
申请日：2014-03-25
申请人： Pfizer Vaccines LLC
发明人： Brian Robert Champion , David Robert Stead , Paul Andrew Wright
IPC分类号： A61K39/395 , C07K17/06 , A61K39/00 , C07K16/42 , A61K39/44 , A61K47/48 , A61K38/10 , A61K39/385 , C07K4/12 , C07K7/08
CPC分类号： C07K17/06 , A61K38/10 , A61K39/0005 , A61K39/385 , A61K39/44 , A61K47/48023 , A61K47/54 , A61K2039/55505 , A61K2039/55561 , A61K2039/55566 , A61K2039/6037 , A61K2039/6075 , A61K2039/6081 , A61K2039/70 , A61K2300/00 , C07K4/12 , C07K7/08 , C07K16/4291 , C07K2317/52 , C07K2317/526 , C07K2317/528 , C07K2319/55 , Y10S424/805 , Y10S424/81 , Y10S530/806 , Y10S530/862 , Y10S530/866 , Y10S530/868
摘要： The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
摘要翻译：本发明涉及提供包含抗原性IgE肽的新型免疫原，优选与免疫原性载体连接，包含免疫原的组合物，以及预防，治疗或减轻IgE介导的病症的方法。本发明还涉及这些药物的生产方法，免疫原性组合物及其药物合成及其在药物中的用途。

3. 发明授权

US09249198B2 Neisseria meningitidis antigens and compositions 有权
公开(公告)号：US09249198B2
公开(公告)日：2016-02-02
申请号：US14450082
申请日：2014-08-01
申请人： GlaxoSmithKline Biologicals SA
发明人： Claire Fraser , Cesira Galeotti , Guido Grandi , Erin Hickey , Vega Masignani , Marirosa Mora , Jeremy Petersen , Mariagrazia Pizza , Rino Rappuoli , Giulio Ratti , Vincenzo Scarlato , Maria Scarselli , Herve Tettelin , J. Craig Venter
IPC分类号： C12P21/00 , C12N15/00 , C12N15/09 , C07K14/22 , A61K38/00 , A61K39/00 , A61K39/095
CPC分类号： C07K14/22 , A61K38/00 , A61K39/00 , A61K39/095 , A61K2039/55505 , Y10S530/806 , Y10S530/825
摘要： The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

4. 发明授权

US09139621B2 Neisseria meningitidis antigens and compositions 有权
公开(公告)号：US09139621B2
公开(公告)日：2015-09-22
申请号：US13070448
申请日：2011-03-23
申请人： Claire Fraser , Cesira Galeotti , Guido Grandi , Erin Hickey , Vega Masignani , Marirosa Mora , Jeremy Petersen , Mariagrazia Pizza , Rino Rappuoli , Giulio Ratti , Vincenzo Scarlato , Maria Scarselli , Herve Tettelin , J. Craig Venter
发明人： Claire Fraser , Cesira Galeotti , Guido Grandi , Erin Hickey , Vega Masignani , Marirosa Mora , Jeremy Petersen , Mariagrazia Pizza , Rino Rappuoli , Giulio Ratti , Vincenzo Scarlato , Maria Scarselli , Herve Tettelin , J. Craig Venter
IPC分类号： C07K14/22 , A61K39/095 , A61K39/00 , A61K38/00
CPC分类号： C07K14/22 , A61K38/00 , A61K39/00 , A61K39/095 , A61K2039/55505 , Y10S530/806 , Y10S530/825
摘要： The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

5. 发明申请

US20150118256A1 IGE CH3 Peptide Vaccine 审中-公开
标题翻译： IGE CH3肽疫苗
公开(公告)号：US20150118256A1
公开(公告)日：2015-04-30
申请号：US14225258
申请日：2014-03-25
申请人： Pfizer Vaccines LLC
发明人： Brian Robert Champion , David Robert Stead , Paul Andrew Wright
IPC分类号： A61K39/44 , A61K47/48 , C07K17/06
CPC分类号： C07K17/06 , A61K38/10 , A61K39/0005 , A61K39/385 , A61K39/44 , A61K47/48023 , A61K47/54 , A61K2039/55505 , A61K2039/55561 , A61K2039/55566 , A61K2039/6037 , A61K2039/6075 , A61K2039/6081 , A61K2039/70 , A61K2300/00 , C07K4/12 , C07K7/08 , C07K16/4291 , C07K2317/52 , C07K2317/526 , C07K2317/528 , C07K2319/55 , Y10S424/805 , Y10S424/81 , Y10S530/806 , Y10S530/862 , Y10S530/866 , Y10S530/868
摘要： The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier, compositions comprising the immunogens, and methods for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.
摘要翻译：本发明涉及提供包含抗原性IgE肽的新型免疫原，优选与免疫原性载体连接，包含免疫原的组合物，以及预防，治疗或减轻IgE介导的病症的方法。本发明还涉及这些药物的生产方法，免疫原性组合物及其药物合成及其在药物中的用途。

6. 发明申请

US20140235819A1 Deuterated Cyclosporine Analogs and Methods of Making the Same 审中-公开
标题翻译：氘代环孢霉素类似物及其制备方法
公开(公告)号：US20140235819A1
公开(公告)日：2014-08-21
申请号：US14182231
申请日：2014-02-17
申请人： Aurinia Pharmaceuticals, Inc.
发明人： Selvaraj A. Naicker , Randall W. Yatscoff , Robert T. Foster
IPC分类号： C07K7/64
CPC分类号： C07K7/645 , A61K38/00 , C07B59/008 , C07K1/13 , C07K7/64 , Y10S530/806 , Y10S530/807
摘要： Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabo-lism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and methods of producing immunosuppression with reduced toxicity using the disclosed cyclosporine derivatives.
摘要翻译：公开了与天然存在的和其他目前已知的环孢菌素和环孢菌素衍生物相比具有增强的功效和降低的毒性的环孢菌素衍生物。本发明的环孢菌素衍生物通过以下方式通过环孢菌素A（CsA）分子的化学和同位素取代产生：（1）氨基酸1的化学取代和任选的氘取代; 和（2）在环孢菌素A分子如氨基酸1,4,9的代谢主要关键位置处的氘替代。还公开了产生环孢菌素衍生物的方法和使用所公开的环孢菌素衍生物产生毒性降低的免疫抑制的方法。

7. 发明申请

US20140142277A1 CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS 审中-公开
标题翻译：环孢素类似物混合物及其作为免疫调节剂的使用
公开(公告)号：US20140142277A1
公开(公告)日：2014-05-22
申请号：US14042226
申请日：2013-09-30
申请人： Aurinia Pharmaceuticals Inc.
发明人： Selvaraj A. Naicker , Randall W. Yatscoff , Robert T. Foster
IPC分类号： C07K7/64
CPC分类号： C07K7/645 , A61K9/0095 , A61K9/1075 , A61K9/4858 , A61K38/00 , A61K38/13 , B82Y5/00 , C07K7/64 , Y10S530/806
摘要： The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
摘要翻译：本发明涉及结构类似于环孢霉素A的环孢菌素类似物的异构体混合物。该混合物具有比单个异构体和天然存在的和其它目前已知的环孢菌素和环孢菌素衍生物更强的功效和降低的毒性。本发明的实施方案涉及称为ISATX247的环孢菌素A类似物的顺式和反式异构体及其衍生物。 ISATX247异构体的混合物显示与天然存在的和目前已知的环孢菌素相比，其效力和毒性降低的组合。 ISATX247异构体和烷基化，芳基化和氘代衍生物通过立体选择性途径合成，其中反应的特定条件决定了立体选择性的程度。基于混合物的总重量，混合物中异构体的比例可以为（E） - 异构体的约10至90重量％至（Z） - 异构体的约90至10重量％。

8. 发明授权

US08524251B2 Neisseria meningitidis antigens and compositions 有权
公开(公告)号：US08524251B2
公开(公告)日：2013-09-03
申请号：US13359471
申请日：2012-01-26
申请人： Claire Fraser , Cesira Galeotti , Guido Grandi , Erin Hickey , Vega Masignani , Marirosa Mora , Jeremy Petersen , Mariagrazia Pizza , Rino Rappuoli , Giulio Ratti , Vincenzo Scarlato , Maria Scarselli , Herve Tettelin , J. Craig Venter
发明人： Claire Fraser , Cesira Galeotti , Guido Grandi , Erin Hickey , Vega Masignani , Marirosa Mora , Jeremy Petersen , Mariagrazia Pizza , Rino Rappuoli , Giulio Ratti , Vincenzo Scarlato , Maria Scarselli , Herve Tettelin , J. Craig Venter
IPC分类号： A61K39/095 , A61K39/02 , A61K38/00 , C07K1/00
CPC分类号： C07K14/22 , A61K38/00 , A61K39/00 , A61K39/095 , A61K2039/55505 , Y10S530/806 , Y10S530/825
摘要： The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.

9. 发明申请

US20130078280A1 CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS 审中-公开
标题翻译：环孢素类似物混合物及其作为免疫调节剂的使用
公开(公告)号：US20130078280A1
公开(公告)日：2013-03-28
申请号：US13684574
申请日：2012-11-26
申请人： Selvaraj A. Naicker , Randall W. Yatscoff , Robert T Foster
发明人： Selvaraj A. Naicker , Randall W. Yatscoff , Robert T Foster
IPC分类号： A61K38/13
CPC分类号： C07K7/645 , A61K9/0095 , A61K9/1075 , A61K9/4858 , A61K38/00 , A61K38/13 , B82Y5/00 , C07K7/64 , Y10S530/806
摘要： The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
摘要翻译：本发明涉及结构类似于环孢霉素A的环孢菌素类似物的异构体混合物。该混合物具有比单个异构体和天然存在的和其它目前已知的环孢菌素和环孢菌素衍生物更强的功效和降低的毒性。本发明的实施方案涉及称为ISATX247的环孢菌素A类似物的顺式和反式异构体及其衍生物。 ISATX247异构体的混合物显示与天然存在的和目前已知的环孢菌素相比，其效力和毒性降低的组合。 ISATX247异构体和烷基化，芳基化和氘代衍生物通过立体选择性途径合成，其中反应的特定条件决定了立体选择性的程度。基于混合物的总重量，混合物中异构体的比例可以为（E） - 异构体的约10至90重量％至（Z） - 异构体的约90至10重量％。

10. 发明申请

US20120321659A1 HBV CORE ANTIGEN PARTICLES WITH MULTIPLE IMMUNOGENIC COMPONENTS ATTACHED VIA PEPTIDE LIGANDS 审中-公开
标题翻译：通过肽配体连接多种免疫组分的HBV核心抗原颗粒
公开(公告)号：US20120321659A1
公开(公告)日：2012-12-20
申请号：US13456996
申请日：2012-04-26
申请人： Kenneth Murray
发明人： Kenneth Murray
IPC分类号： A61K39/39 , C07K17/10 , C07K19/00 , G01N33/53 , A61P31/04 , A61P33/02 , A61P31/20 , A61P33/06 , A61P37/08 , A61P31/22 , A61P31/10 , A61P33/00 , C07K17/02 , A61P31/14
CPC分类号： A61K39/385 , A61K39/00 , A61K39/12 , A61K39/29 , A61K39/292 , A61K2039/5258 , A61K2039/6075 , A61K2039/627 , A61K2039/64 , C07K14/005 , C07K2319/00 , C07K2319/70 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , C12N2730/10134 , G01N33/56983 , G01N2333/02 , G01N2469/20 , Y02A50/386 , Y02A50/388 , Y02A50/396 , Y02A50/412 , Y02A50/464 , Y02A50/466 , Y02A50/484 , Y02A50/53 , Y02A50/54 , Y02A50/58 , Y02A50/59 , Y02A50/60 , Y10S530/806 , Y10S530/81
摘要： This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.
摘要翻译：本发明涉及以多种免疫原特异性为特征的乙型肝炎病毒（HBV）核心抗原颗粒。更具体地，本发明涉及包含免疫原，表位或其它相关结构的HBV核心抗原颗粒，其通过配体选择性地结合HBV核心蛋白的配体进行交联。这样的颗粒可以用作各种免疫原性表位的递送系统，包括HBV衣壳结合肽，其有利地还通过阻断HBV核心蛋白和HBV表面蛋白之间的相互作用来抑制和干扰HBV病毒组装。不同免疫原和/或衣壳结合肽配体的混合物可以交联到相同的HBV核心颗粒。这样得到的多组分或多价HBV核心颗粒可以有利地用于治疗和预防性疫苗和组合物，以及使用它们的诊断组合物和方法中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式